ProCE Banner Activity

How I Individualize TKI Therapy for Patients With CML

Clinical Thought
In this commentary, I describe the approaches and considerations we use in our clinic to tailor TKI treatment for individual patients with chronic myeloid leukemia and take a look at emerging data from ASH 2021.

Released: December 13, 2021

Expiration: December 12, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Faculty Disclosure

Primary Author

Jerald Radich, MD

Professor
Translational Science and Therapeutics Division
Kurt Enslein Endowed Chair
Fred Hutch Cancer Center
Seattle, WA

Jerald Radich, MD, has disclosed that he has received consulting fees from Amgen, Bristol Myers Squibb, Genentech, and Novartis.